A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 TrialDominick J. Angiolillo, Mark B. Effron, J J Badimón et al.|European Heart Journal|2011Cited by 182
Increased Platelet Inhibition After Switching From Maintenance Clopidogrel to Prasugrel in Patients With Acute Coronary SyndromesDominick J. Angiolillo, Mark B. Effron, Jorge F. Saucedo et al.|Journal of the American College of Cardiology|2010Cited by 168
Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Patients With Stable Coronary Artery DiseaseDominick J. Angiolillo, Dietmar Trenk, Fred Lipkin et al.|Journal of the American College of Cardiology|2013Cited by 92
Effects of Abciximab, Ticlopidine, and Combined Abciximab/Ticlopidine Therapy on Platelet and Leukocyte Function in Patients Undergoing Coronary AngioplastyBecky J. Fredrickson, Larry V. McIntire, Nancy A. Turner et al.|Circulation|2000Cited by 42
The Onset of Inhibition of Platelet Aggregation With Prasugrel Compared With Clopidogrel Loading Doses Using Gatekeeping Analysis of Integrated Clinical Pharmacology DataBaojin Zhu, Kenneth J. Winters, Mark B. Effron et al.|Journal of Cardiovascular Pharmacology|2011Cited by 20